BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 23698071)

  • 1. Selective inhibition of p300 HAT blocks cell cycle progression, induces cellular senescence, and inhibits the DNA damage response in melanoma cells.
    Yan G; Eller MS; Elm C; Larocca CA; Ryu B; Panova IP; Dancy BM; Bowers EM; Meyers D; Lareau L; Cole PA; Taverna SD; Alani RM
    J Invest Dermatol; 2013 Oct; 133(10):2444-2452. PubMed ID: 23698071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor.
    Bowers EM; Yan G; Mukherjee C; Orry A; Wang L; Holbert MA; Crump NT; Hazzalin CA; Liszczak G; Yuan H; Larocca C; Saldanha SA; Abagyan R; Sun Y; Meyers DJ; Marmorstein R; Mahadevan LC; Alani RM; Cole PA
    Chem Biol; 2010 May; 17(5):471-82. PubMed ID: 20534345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Valproic acid exposure decreases Cbp/p300 protein expression and histone acetyltransferase activity in P19 cells.
    Lamparter CL; Winn LM
    Toxicol Appl Pharmacol; 2016 Sep; 306():69-78. PubMed ID: 27381264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An inhibitor of the acetyltransferases CBP/p300 exerts antineoplastic effects on gastrointestinal stromal tumor cells.
    Gu ML; Wang YM; Zhou XX; Yao HP; Zheng S; Xiang Z; Ji F
    Oncol Rep; 2016 Nov; 36(5):2763-2770. PubMed ID: 27633918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone acetyltransferase p300/CBP inhibitor C646 blocks the survival and invasion pathways of gastric cancer cell lines.
    Wang YM; Gu ML; Meng FS; Jiao WR; Zhou XX; Yao HP; Ji F
    Int J Oncol; 2017 Dec; 51(6):1860-1868. PubMed ID: 29075795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic regulation of proliferation and invasion in hepatocellular carcinoma cells by CBP/p300 histone acetyltransferase activity.
    Inagaki Y; Shiraki K; Sugimoto K; Yada T; Tameda M; Ogura S; Yamamoto N; Takei Y; Ito M
    Int J Oncol; 2016 Feb; 48(2):533-40. PubMed ID: 26676548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C646, a selective small molecule inhibitor of histone acetyltransferase p300, radiosensitizes lung cancer cells by enhancing mitotic catastrophe.
    Oike T; Komachi M; Ogiwara H; Amornwichet N; Saitoh Y; Torikai K; Kubo N; Nakano T; Kohno T
    Radiother Oncol; 2014 May; 111(2):222-7. PubMed ID: 24746574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Lineage-specific MITF Pathway in Human Melanoma Cell Lines by A-485, the Selective Small-molecule Inhibitor of p300/CBP.
    Wang R; He Y; Robinson V; Yang Z; Hessler P; Lasko LM; Lu X; Bhathena A; Lai A; Uziel T; Lam LT
    Mol Cancer Ther; 2018 Dec; 17(12):2543-2550. PubMed ID: 30266801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The histone acetyltransferase p300 inhibitor C646 reduces pro-inflammatory gene expression and inhibits histone deacetylases.
    van den Bosch T; Boichenko A; Leus NGJ; Ourailidou ME; Wapenaar H; Rotili D; Mai A; Imhof A; Bischoff R; Haisma HJ; Dekker FJ
    Biochem Pharmacol; 2016 Feb; 102():130-140. PubMed ID: 26718586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
    Lasko LM; Jakob CG; Edalji RP; Qiu W; Montgomery D; Digiammarino EL; Hansen TM; Risi RM; Frey R; Manaves V; Shaw B; Algire M; Hessler P; Lam LT; Uziel T; Faivre E; Ferguson D; Buchanan FG; Martin RL; Torrent M; Chiang GG; Karukurichi K; Langston JW; Weinert BT; Choudhary C; de Vries P; Van Drie JH; McElligott D; Kesicki E; Marmorstein R; Sun C; Cole PA; Rosenberg SH; Michaelides MR; Lai A; Bromberg KD
    Nature; 2017 Oct; 550(7674):128-132. PubMed ID: 28953875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CBP/p300 inhibitor C646 prevents high glucose exposure induced neuroepithelial cell proliferation.
    Bai B; Zhang Q; Wan C; Li D; Zhang T; Li H
    Birth Defects Res; 2018 Aug; 110(14):1118-1128. PubMed ID: 30114346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MITF Expression Predicts Therapeutic Vulnerability to p300 Inhibition in Human Melanoma.
    Kim E; Zucconi BE; Wu M; Nocco SE; Meyers DJ; McGee JS; Venkatesh S; Cohen DL; Gonzalez EC; Ryu B; Cole PA; Alani RM
    Cancer Res; 2019 May; 79(10):2649-2661. PubMed ID: 30910803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A histone acetyltransferase p300 inhibitor C646 induces cell cycle arrest and apoptosis selectively in AML1-ETO-positive AML cells.
    Gao XN; Lin J; Ning QY; Gao L; Yao YS; Zhou JH; Li YH; Wang LL; Yu L
    PLoS One; 2013; 8(2):e55481. PubMed ID: 23390536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current development of CBP/p300 inhibitors in the last decade.
    He ZX; Wei BF; Zhang X; Gong YP; Ma LY; Zhao W
    Eur J Med Chem; 2021 Jan; 209():112861. PubMed ID: 33045661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines.
    Santer FR; Höschele PP; Oh SJ; Erb HH; Bouchal J; Cavarretta IT; Parson W; Meyers DJ; Cole PA; Culig Z
    Mol Cancer Ther; 2011 Sep; 10(9):1644-55. PubMed ID: 21709130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors.
    Lu W; Xiong H; Chen Y; Wang C; Zhang H; Xu P; Han J; Xiao S; Ding H; Chen Z; Lu T; Wang J; Zhang Y; Yue L; Liu YC; Zhang C; Yang Y; Jiang H; Chen K; Zhou B; Luo C
    Bioorg Med Chem; 2018 Nov; 26(20):5397-5407. PubMed ID: 30297119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The structural basis of protein acetylation by the p300/CBP transcriptional coactivator.
    Liu X; Wang L; Zhao K; Thompson PR; Hwang Y; Marmorstein R; Cole PA
    Nature; 2008 Feb; 451(7180):846-50. PubMed ID: 18273021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of long chain alkylidenemalonates as novel small molecule modulators of histone acetyltransferases.
    Sbardella G; Castellano S; Vicidomini C; Rotili D; Nebbioso A; Miceli M; Altucci L; Mai A
    Bioorg Med Chem Lett; 2008 May; 18(9):2788-92. PubMed ID: 18434144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP.
    Wu F; Hua Y; Kaochar S; Nie S; Lin YL; Yao Y; Wu J; Wu X; Fu X; Schiff R; Davis CM; Robertson M; Ehli EA; Coarfa C; Mitsiades N; Song Y
    J Med Chem; 2020 May; 63(9):4716-4731. PubMed ID: 32314924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of novel inhibitors of histone acetyltransferases.
    Eliseeva ED; Valkov V; Jung M; Jung MO
    Mol Cancer Ther; 2007 Sep; 6(9):2391-8. PubMed ID: 17876038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.